Study reveals how well saudi doctors follow safety rules for common arthritis drug
NCT ID NCT06714461
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether healthcare professionals in Saudi Arabia are aware of and follow safety measures for the drug leflunomide, used for rheumatoid and psoriatic arthritis. Researchers surveyed 302 doctors and pharmacists to see if they received and read safety materials, and if they counseled patients and ordered proper lab tests. The goal was to assess how well the extra safety steps are working, not to test a new treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanofi-Aventis
Chilly-Mazarin, 91380, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new shoulder implant restore Pain-Free movement?
- Can a less invasive hip surgery speed up recovery?
- Which hip implant lasts longer? a Head-to-Head trial aims to find out
- Can pregnancy and neurological disease coexist safely? a new registry seeks answers
- Can group learning make biotherapy safer for arthritis patients?
- Can a specialized hand exercise protocol restore grip and ease pain in rheumatoid arthritis?